The antitumor effect of arsenic trioxide on hepatocellular carcinoma is enhanced by andrographolide

Xuhua Duan; Tengfei Li; Xinwei Han; Jianzhuang Ren; Pengfei Chen; Hao Li; Shaojun Gong

doi:10.18632/oncotarget.18677

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The antitumor effect of arsenic trioxide on hepatocellular carcinoma is enhanced by andrographolide

Xuhua Duan, Tengfei Li, Xinwei Han _, Jianzhuang Ren, Pengfei Chen, Hao Li and Shaojun Gong

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:90905-90915. https://doi.org/10.18632/oncotarget.18677

Metrics: PDF 1555 views | HTML 2048 views | ?

Abstract

Xuhua Duan1,*, Tengfei Li1,*, Xinwei Han1,#, Jianzhuang Ren1,#, Pengfei Chen1, Hao Li1 and Shaojun Gong1

1Department of Interventional Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, People’s Republic of China

*These authors contributed equally to this work and share co-first authorship

#These authors contributed equally to this work

Correspondence to:

Xinwei Han, email: [email protected]

Jianzhuang Ren, email: [email protected]

Keywords: andrographolide, As₂O₃, HepG2 cells, apoptosis, EphB4

Received: February 14, 2017 Accepted: June 02, 2017 Published: June 27, 2017

ABSTRACT

High concentrations of arsenic trioxide (As₂O₃) are used to treat acute promyelocytic leukemia and solid tumors, with negative side effects to normal cells. Andrographolide is a traditional Chinese medicine that exerts anti-cancer, anti-inflammatory, anti-virus, and anti-diabetic effects. Here, we tested the effects of combined andrographolide with As₂O₃ against hepatocellular carcinoma (HCC). We found that by increasing apoptosis, andrographolide synergistically enhanced the anti-tumor effects of As2O3 in HepG2 cells in vitro and in vivo. Furthermore, results from our microarray assays and experiments with mouse xenografts showed that EphB4 was downregulated by the combination of As₂O₃ plus andrographolide. These findings suggest that the combination of andrographolide and As₂O₃ could yield therapeutic benefits in the treatment of HCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18677

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

The antitumor effect of arsenic trioxide on hepatocellular carcinoma is enhanced by andrographolide

Abstract